Big pharma influencing FDA decisions
About half a million Canadians have dementia, and cases are growing around the world.
That means doctors and drug companies are eager to find new treatments, and as a result of that the U.S. Food and Drug Administration says it wants to relax the rules for clinical trials on new Alzheimer's medications.
Airplay's house doctor Brian Goldman isn't sure that is a good idea.
Click on the link below to hear him speak with Dave.